retatrutide triple agonist glp-1 gip glucagon phase 2 obesity hormone receptor for metabolic dysfunction-associated steatotic liver disease: a randomized 2a trial Retatrutide: Triple-Agonist for Obesity and

Calcitonin receptor, calcitonin gene-related peptide and amylin distribution in C1/2 dorsal root ganglia

Over time, this increases the risk of cardiovascular disease and other complications

Currently, dietary modifications, along with agents such as acarbose, diazoxide, and somatostatin analogs, continue to represent the standard management approach despite challenges related to tolerability, adherence, and variable efficacy

For many individuals, lifestyle changes like diet and exercise may not be enough to achieve sustainable weight loss, making medications a vital component of a comprehensive weight management plan